Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Q3 FY2025 Earnings Presentation
11 slides from Vitrafy Life Sciences's earnings presentation, May 2, 2025
Slide 1: Vitrafy Q3 FY25 Investor Presentation
ASX ANNOUNCEMENT 2 May 2025 Vitrafy Q3 FY25 Investor Presentation Vitrafy Life Sciences Limited (ASX: VFY), (Vitrafy or Company) attaches the presentation to be delivered at today’s Q3 FY25 Investor Briefing. ### ENDS ### For personal use only This announcement is authorised by the CEO of Vitrafy Li
Slide 2: Quarterly Activities Report Q3, Financial Year 2025
For personal use only Quarterly Activities Report Q3, Financial Year 2025
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (“Vitrafy” or “the Company”). This expectations in relation to any such statements or any change in events, conditions or circumstances on which any Document is current as at the date of th
Slide 4: Q3 Activity Highlights
Q3 Activity Highlights USAISR Phase 1 study completed For personal use only Post-thaw platelet recovery >88%, functionality measurements exceeding regulatory standards Product development on-schedule for go-to-market launch in 2025 Vitrafy’s Cryopreservation Unit 2.0 (VCU2) and upgrade of the LifeCh
Slide 5: Animal Health - Aquaculture
Animal Health - Aquaculture Huon Summer fertilisation program For personal use only • Vitrafy cryopreserved salmon milt Summer 2025 Fertilisation % shows comparable fertilisation 100% to fresh milt. 90% • May 2025 cryopreservation cycle – 750 packs (up from 500 in 80% 75% 72% 2024). 70% 60% 50% 45%
Slide 6: Animal Health - Bovine
Animal Health - Bovine For personal use only Select Sires, Inc. • Collaboration with Select Sires, Inc. progressing. • Scope and planning finalised for Phase 2 onsite trial in Ohio. • Results and next steps expected in Q4. 5
Slide 7: Human Health progress
Human Health progress For personal use only Blood Platelets USAISR Phase 1 study: 24 units tested; post-thaw recovery: >88% Functionality measurements: exceed industry and regulatory requirements Phase 2 study in development to validate higher throughput Commercialisation planning to commence in 202
Slide 8: Operational capability
Operational capability VCU2 development For personal use only $4.8m Industry Growth Program Grant awarded by Australian Government to support VCU2 development. Co-developed with HealthTech company, Planet Innovation. Go-to-market launch on-schedule for H2 CY2025. LifeChain Software Upgrade Enhanced
Slide 9: Financial Update
Financial Update For personal use only Total Liquidity: Expenditure A$34.0m ~A$1.1m monthly cash A$13.9m cash outflow A$20.1m short term A$(0.5)m net change financial assets Q4 financial outlook: Focussed capital allocation on commercialisation activities. Increased headcount and product development
Slide 10: Q4 Outlook
Q4 Outlook Commercialisation focus; build For personal use only capability in key markets Build business development pipeline Product launch of next generation devices 9
Slide 11: Thank you
Thank you For personal use only Contact Information Investor Enquiries Email: investors@vitrafy.com Vitrafy Life Sciences Limited ACN 622 720 254 vitrafy.com
Vitrafy Life Sciences — Q3 FY2025 Earnings Presentation on 6ix